BMO Capital Markets lowered shares of Audentes Therapeutics (NASDAQ:BOLD) from an outperform rating to a market perform rating in a research note released on Tuesday morning, Benzinga reports. They currently have $60.00 target price on the biotechnology company’s stock, up from their previous target price of $47.00.
BOLD has been the subject of a number of other reports. BidaskClub downgraded Audentes Therapeutics from a sell rating to a strong sell rating in a report on Friday, November 8th. Evercore ISI raised Audentes Therapeutics from an in-line rating to an outperform rating in a research note on Wednesday, November 27th. HC Wainwright reissued a buy rating and issued a $48.00 price objective on shares of Audentes Therapeutics in a research note on Friday, November 8th. Robert W. Baird upgraded Audentes Therapeutics from an underperform rating to a neutral rating in a research report on Tuesday. Finally, ValuEngine cut Audentes Therapeutics from a buy rating to a hold rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company’s stock. Audentes Therapeutics currently has a consensus rating of Hold and an average target price of $44.50.
NASDAQ:BOLD opened at $58.93 on Tuesday. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $59.01. The firm’s fifty day moving average is $28.32 and its 200-day moving average is $33.21. The firm has a market cap of $1.33 billion, a P/E ratio of -17.33 and a beta of 1.77.
In related news, Director Louis G. Lange sold 10,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $32.16, for a total value of $321,600.00. Following the completion of the sale, the director now directly owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew R. Patterson sold 14,426 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $30.00, for a total value of $432,780.00. Following the transaction, the chief executive officer now directly owns 127,820 shares in the company, valued at $3,834,600. The disclosure for this sale can be found here. 5.30% of the stock is owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in BOLD. Meeder Asset Management Inc. increased its holdings in shares of Audentes Therapeutics by 578.5% during the second quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 619 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Audentes Therapeutics by 50.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,005 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Audentes Therapeutics by 1.8% in the 3rd quarter. Rhumbline Advisers now owns 61,051 shares of the biotechnology company’s stock worth $1,715,000 after purchasing an additional 1,070 shares in the last quarter. Aperio Group LLC bought a new position in shares of Audentes Therapeutics in the 2nd quarter worth $46,000. Finally, Swiss National Bank grew its position in Audentes Therapeutics by 2.1% in the 2nd quarter. Swiss National Bank now owns 67,500 shares of the biotechnology company’s stock valued at $2,556,000 after purchasing an additional 1,400 shares during the period. 98.08% of the stock is owned by hedge funds and other institutional investors.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
See Also: What is total return in investing?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.